RM

Ravi Mahanthi

Active Director Director DIN 09694871
DIN 09694871 First appointment Aug 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2022
Shareholding value •••• Premium profile

About Ravi Mahanthi

Data last updated:

Ravi Mahanthi is a Director at Celera Pharma Private Limited (since 2022). The company operates in Pharma. Celera Pharma Private Limited reported revenue of ₹22.48 Cr (FY 2025).

DIN 09694871
Primary Designation Director
Industry Pharma
First Appointment 04 Aug 2022
Oldest Company Age 15 yrs
Largest company Celera Pharma Private Limited · ₹22.48 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Celera Pharma Private Limited U24232TG2011PTC072493
Director04 Aug 20222011₹22.48 Cr (FY 2025)Active

Board colleagues of Ravi Mahanthi

NameDINCompanyDesignation
Sabitha Kalluri06975630Celera Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Celera Pharma Private Limited
Premium access

Shareholding and investment profile for Ravi Mahanthi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravi Mahanthi

Ravi Mahanthi currently holds 1 directorship: Celera Pharma Private Limited (Director, since 04 Aug 2022, revenue ₹22.48 Cr (FY 2025)).

Ravi Mahanthi was first appointed on 04 Aug 2022 as Director at Celera Pharma Private Limited.

The current boards of Ravi Mahanthi's companies include Sabitha Kalluri (Celera Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available